GF-001001-00 Cream.A Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of 3 Different Doses of GF-001001-00 Cream Versus Placebo Cream Applied 2 Times Daily for 7 Days in the Treatment of Adult Patients With Secondarily-infected Traumatic Lesions.

Trial Profile

GF-001001-00 Cream.A Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of 3 Different Doses of GF-001001-00 Cream Versus Placebo Cream Applied 2 Times Daily for 7 Days in the Treatment of Adult Patients With Secondarily-infected Traumatic Lesions.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2016

At a glance

  • Drugs Ozenoxacin (Primary)
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Ferrer
  • Most Recent Events

    • 23 Feb 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2008-007055-28).
    • 21 Sep 2012 integrated Eudra Record. no pub history event as this is old. added purpose, treatments
    • 08 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top